Evidence map›Paper›PMID 41283788›Full record

ArticleAsia-Pacific journal of clinical oncology2026

Prognostic Significance of Deubiquitinase OTUD7B in NK/T-Cell Lymphoma.

Yizhen Liu, Shujuan Wen, Zuguang Xia, Shiyu Jiang, Guangliang Chen, Ailing Gui, Ling Yang, Shune Yang, Xuejun Ma, Qunling Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yizhen LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-1320-7364
Shujuan WenThe Affiliated Cancer Hospital of Xinjiang Medical University, Shanghai, China.
Zuguang XiaDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Shiyu JiangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Guangliang ChenDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Ailing GuiDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Ling YangDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Shune YangThe Affiliated Cancer Hospital of Xinjiang Medical University, Shanghai, China.
Xuejun MaDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qunling ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Funding

the National Natural Science Foundation of China 81670177the National Natural Science Foundation of China 82060041
6 · The paper itself

Abstract

aimOTUD7B (ovarian tumor domain-containing 7B) is a deubiquitinase that has established prognostic significance in diffuse large B-cell lymphoma and various solid tumors. In our present work, we aimed to explore its role in NK/T cell lymphoma (NKTCL).

methodsExpression level of OTUD7B was assessed through immunohistochemistry in 53 NKTCL tissue samples. Statistical analyses were conducted to elucidate correlations between its expression and clinicopathological parameters of patients. Kaplan-Meier survival curves were constructed for survival analyses.

resultsOTUD7B was overexpressed in 41 (77.4%) NK/T tissue samples. Remarkably, patients with OTUD7B overexpression exhibit improved progression-free survival (PFS) (p = 0.021) and overall survival (OS) compared to those with low OTUD7B expression (p = 0.007). Multivariate Cox regression analysis demonstrated that OTUD7B was an independent prognostic indicator for both PFS (p = 0.037, HR = 0.401, 95% CI: 0.169-0.947) and OS (p = 0.043, HR = 0.278, 95% CI: 0.081-0.961) in NTKCL patients.

conclusionOTUD7B could act as a prognostic indicator in NTKCL patients; further investigations remain imperative.

Indexed as

Biomarkers, TumorEndopeptidasesLymphoma, Extranodal NK-T-CellAdultAgedFemaleHumansMaleMiddle AgedPrognosisBiomarkers, TumorEndopeptidasesOTUD7B protein, humanchemotherapyNK/T‐cell lymphomaOTUD7Bprognosissurvival

Identifiers

PMID41283788
PMCPMC13568903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.